Nektar Therapeutics
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ITH0.F | ARTV | CRVS | AKTS | ACRS | BHVN | |
|---|---|---|---|---|---|---|
| Market cap | 1.09B | 320.72M | 860.56M | 894.36M | 554.94M | 1.78B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -2.5 | -9.6 | -7.5 | -4.8 | -6.3 |
| Price/book | 1.4 | 0.9 | 3.8 | 1.8 | 4.2 | 145.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −41.42% | +35.09% | +34.03% | −32.54% | +46.22% | −35.98% |
| Today | +2.04% | +11.38% | +6.01% | +6.42% | +8.33% | +4.05% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ITH0.F news ›Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at Leerink Partners
Posted by Sarita Garza on Oct 13th, 2026 Leerink Partners assumed coverage on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research report released on Monday morning, Marketbeat Ratings reports. The brokerage issued an…
BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target
BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00. The price target implies an upside of 336.3% from the Oct 8 close of $40.80. Positive Initial Legal Outcomes: The favorable outcome of the…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
themarketsdaily.com3
-
tradingview.com3
-
seekingalpha.com2
-
gurufocus.com1
-
kalkinemedia.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.